查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886542

急性骨髓性白血病市场－全球产业规模、份额、趋势、机会和预测，依化疗、地区和竞争格局划分，2020-2030年预测

Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy, By Region, and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球急性骨髓性白血病市场规模为15.6亿美元，预计到2030年将以8.90%的复合年增长率成长至26.3亿美元。急性骨髓性白血病（AML）是一种快速进展的血液和骨髓癌症，其特征是异常髓係原始细胞不受控制地增生。 AML治疗市场的主要驱动因素是该疾病在全球范围内发病率的不断上升，以及老年人口的增长，老年人面临更高的诊断风险。

市场概览
预测期 2026-2030
市场规模：2024年 15.6亿美元
市场规模：2030年 26.3亿美元
复合年增长率：2025-2030年 8.90%
成长最快的细分市场 荷尔蒙疗法
最大的市场 北美洲

主要市场驱动因素

全球急性骨髓性白血病市场主要受益于急性髓性白血病（AML）研究和治疗技术的不断进步。这些创新透过新型药物和治疗策略，拓展了治疗选择，并改善了患者的治疗效果。

主要市场挑战

先进治疗方案的高昂成本严重阻碍了全球急性骨髓性白血病市场的成长。这些高额费用直接影响患者获得可能挽救生命的治疗的机会，从而限制了创新疗法的整体普及率和收入潜力。

主要市场趋势

口服和门诊治疗方案的日益普及，显着重塑了全球急性骨髓性白血病市场，提高了患者的便利性，并减轻了医院基础设施的负担。这些创新方法使得治疗可以在限制较少的环境下进行，从而改善患者的生活品质，尤其是老年患者或合併其他疾病的患者。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球急性骨髓性白血病市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 化疗（阿糖胞苷、蒽环类药物、烷化剂、抗代谢药、酪胺酸激酶抑制剂、荷尔蒙疗法、其他化疗药物）
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美急性骨髓性白血病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲急性骨髓性白血病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区急性骨髓性白血病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲急性骨髓性白血病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲急性骨髓性白血病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章：全球急性骨髓性白血病市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • Bristol-Myers Squibb Company (Celgene Corporation)
  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma
  • Oncolyze Inc.

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 24060

The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.56 Billion
Market Size 2030USD 2.63 Billion
CAGR 2025-20308.90%
Fastest Growing SegmentHormonal therapy
Largest MarketNorth America

Key Market Drivers

The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations.

Key Market Challenges

The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.

Key Market Trends

The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities.

Key Market Players

  • Bristol-Myers Squibb Company (Celgene Corporation)
  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma
  • Oncolyze Inc.

Report Scope:

In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Myeloid Leukemia Market, By Chemotherapy:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal therapy
  • Other chemotherapies

Acute Myeloid Leukemia Market, By Region:

  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.

Available Customizations:

Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Myeloid Leukemia Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal therapy, Other chemotherapies)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. North America Acute Myeloid Leukemia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Chemotherapy
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Myeloid Leukemia Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Chemotherapy
    • 6.3.2. Canada Acute Myeloid Leukemia Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Chemotherapy
    • 6.3.3. Mexico Acute Myeloid Leukemia Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Chemotherapy

7. Europe Acute Myeloid Leukemia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Chemotherapy
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Myeloid Leukemia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Chemotherapy
    • 7.3.2. France Acute Myeloid Leukemia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Chemotherapy
    • 7.3.3. United Kingdom Acute Myeloid Leukemia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Chemotherapy
    • 7.3.4. Italy Acute Myeloid Leukemia Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Chemotherapy
    • 7.3.5. Spain Acute Myeloid Leukemia Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Chemotherapy

8. Asia Pacific Acute Myeloid Leukemia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Chemotherapy
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Acute Myeloid Leukemia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Chemotherapy
    • 8.3.2. India Acute Myeloid Leukemia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Chemotherapy
    • 8.3.3. Japan Acute Myeloid Leukemia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Chemotherapy
    • 8.3.4. South Korea Acute Myeloid Leukemia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Chemotherapy
    • 8.3.5. Australia Acute Myeloid Leukemia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Chemotherapy

9. Middle East & Africa Acute Myeloid Leukemia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Chemotherapy
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Chemotherapy
    • 9.3.2. UAE Acute Myeloid Leukemia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Chemotherapy
    • 9.3.3. South Africa Acute Myeloid Leukemia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Chemotherapy

10. South America Acute Myeloid Leukemia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Chemotherapy
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Chemotherapy
    • 10.3.2. Colombia Acute Myeloid Leukemia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Chemotherapy
    • 10.3.3. Argentina Acute Myeloid Leukemia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Chemotherapy

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Acute Myeloid Leukemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb Company (Celgene Corporation)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Genmab AS
  • 15.4. Otsuka Holdings Co. Ltd
  • 15.5. Sanofi-Aventis (Genzyme Corporation)
  • 15.6. Teva Pharmaceutical (Cephalon Inc.)
  • 15.7. Pfizer Inc.
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Sunesis Pharmaceuticals Inc.
  • 15.10. Astellas Pharma
  • 15.11. Oncolyze Inc.

16. Strategic Recommendations

17. About Us & Disclaimer